2020HER2阳性乳腺癌治疗进展(最新推荐).pptx

HER2阳性乳腺癌治疗进展;主要内容;主要内容;主要内容;Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): br /a randomized phase 3 trial;PHOEBE phase 3 trial: study design;Key baseline characteristics;Primary endpoint: PFS assessed by BICR;PFS consistency;PFS in subgroups;PFS by resistance to trastuzumab;Response rate and duration;OS;Overview of adverse events (AEs);Most comment grade ≥3 treatment-related AEs;Diarrhea with pyrotinib combined therapy: low severity, early onset, short duration, reversibility, seldom leading to treatment termination;Conclusions;主要内容;Background;HER2CLIMB-PFS;HER2CLIMB-OS;HER2CLIMB-PFS (BM);HER2CLIMB Primary Analysis Results;HER-2 Brain Metastases;Breast cancer and Brain Metastases;;BM trials review;Summary of key trials for HER2+ brain mets;Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Previously Treated HER2+ Metastatic Breast Cancer with Brain Metastases (HER2CLIMB);HER2CLIMB Analysis of Patients with Brain Metastases;Baseline Characteristics of HER2CLIMB Patients with Brain Metastases;CNS-PFS Benefit in Patients with Brain Metastases;OS Benefit in Patients with Brain Metastases;CNS-PFS Benefit in Patients with Active Brain Metastases;OS Benefit in Patients with Active Brain Metastases;CNS-PFS Benefit in Patients with Stable Brain Metastases;OS in Patients with Stable Brain Metastases;Intracranial Response Rate (ORR-IC) in Patients with Active Brain Metastases and Measurable Intracranial Lesions at Baseline;Conclusions;主要内容;主要内容;Primary Analysis of KAITLIN: A Phase 3 Study of Trastuzumab Emtansine (T-DM1) + Pertuzumab Versus Trastuzumab + Pertuzumab + Taxane, after Anthracyclines as Adjuvant Therapy for High-Risk HER2-Positive Early Breast Cancer;KAITLIN Study Design;Study Population;Baseline Characteristics of ITT Population (1)br /;Characteristics of ITT Population (2): Stratification Factorsbr /;Baseline Characteristics of ITT Population (3)br /;Primary Endpoint: IDFS, Node-Positive Disease;P